LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by on May 17th, 2026

Shares of LivaNova PLC (NASDAQ:LIVN – Get Free Report) have earned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $77.2222.

Several research analysts have commented on LIVN shares. Stifel Nicolaus set a $80.00 target price on shares of LivaNova in a report on Wednesday, February 25th. Piper Sandler reiterated an “overweight” rating and issued a $85.00 target price on shares of LivaNova in a report on Thursday, February 19th. Robert W. Baird decreased their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Mizuho raised their target price on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th.

Read Our Latest Stock Analysis on LIVN

LivaNova Stock Performance

Shares of LIVN opened at $70.00 on Tuesday. LivaNova has a one year low of $41.01 and a one year high of $73.30. The company has a 50-day moving average of $64.25 and a two-hundred day moving average of $62.80. The stock has a market cap of $3.85 billion, a price-to-earnings ratio of 35.90 and a beta of 0.82. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11.

LivaNova (NASDAQ:LIVN – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company had revenue of $362.26 million during the quarter, compared to analysts’ expectations of $346.05 million. During the same period last year, the company posted $0.88 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities research analysts expect that LivaNova will post 3.72 earnings per share for the current year.

Institutional Trading of LivaNova

Hedge funds have recently made changes to their positions in the stock. Envestnet Asset Management Inc. lifted its position in shares of LivaNova by 168.1% in the third quarter. Envestnet Asset Management Inc. now owns 27,125 shares of the company’s stock worth $1,421,000 after purchasing an additional 17,007 shares in the last quarter. Allianz Asset Management GmbH purchased a new stake in shares of LivaNova in the third quarter worth approximately $7,687,000. LSV Asset Management lifted its position in shares of LivaNova by 25.4% in the third quarter. LSV Asset Management now owns 674,610 shares of the company’s stock worth $35,336,000 after purchasing an additional 136,600 shares in the last quarter. Boone Capital Management LLC purchased a new stake in shares of LivaNova in the third quarter worth approximately $8,796,000. Finally, Emerald Mutual Fund Advisers Trust lifted its position in shares of LivaNova by 8.1% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 349,664 shares of the company’s stock worth $18,315,000 after purchasing an additional 26,202 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About LivaNova

(Get Free Report)

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

Featured Stories

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.